Short answers, pulled from the story.
Amgen was established in April 1980 by a small group of venture capitalists who initially named the entity Applied Molecular Genetics. George Rathmann became the first president and chief executive officer in October 1980.
Prolia and XGEVA combined generated $6.7 billion in total revenues during 2024 while Enbrel brought in $3.3 billion alone. Repatha contributed $2.3 billion to 2024 revenues as a treatment for hyperlipidemia or high cholesterol levels.
In October 2022, the company acquired ChemoCentryx for $3.7 billion and purchased Horizon Therapeutics for $27.8 billion the following year. Earlier acquisitions included Five Prime Therapeutics in April 2021 and Rodeo Therapeutics in March 2021.
The global operations of Amgen span dozens of countries with headquarters remaining in Thousand Oaks, California. The Puerto Rico site established in 1993 remains the company's flagship manufacturing location today.
Amgen pleaded guilty and agreed to pay $150 million in criminal penalties because it sold the drug for off-label uses at dosages rejected by regulators. An additional $612 million resolved eleven related whistleblower complaints concerning improper marketing of Aranesp.